AstraZeneca's flagship Tagrisso helps lung cancer patients live longer in pivotal study

AstraZeneca's flagship Tagrisso helps lung cancer patients live longer in pivotal study

Source: 
Endpoints
snippet: 

AstraZeneca is off to a good start in August. After its PARP inhibitor Lynparza scored in a prostate cancer trial earlier this week, the British drugmaker on Friday disclosed that its star cancer drug Tagrisso helped patients with a certain type of lung cancer live longer in a late-stage study.